UK drug bulletin evaluates the place of Sativex in MS spasticity treatment
A UK drug evaluation bulletin reviewed Sativex evidence and noted it was licensed as add-on therapy for moderate-to-severe MS spasticity when other treatments have failed.
Quick Facts
What This Study Found
This Drug and Therapeutics Bulletin evaluation reviewed the clinical evidence for Sativex (cannabis extract containing THC and CBD) for MS-related spasticity. MS affects about 60,000 people in England and Wales, with a lifetime UK risk of 1 in 1,000.
Spasticity was described as a common symptom requiring complex drug combinations that were often only partially effective with unacceptable side effects. Sativex was the first licensed cannabinoid preparation for medical use, approved specifically for patients with moderate-to-severe spasticity who had not responded adequately to other anti-spasticity medications.
The license required patients to demonstrate clinically significant improvement during an initial trial period before continuing treatment.
Key Numbers
MS affects ~60,000 people in England and Wales. UK lifetime risk: 1 in 1,000. Sativex licensed for moderate-to-severe spasticity after other treatments fail.
How They Did This
Drug evaluation review by the Drug and Therapeutics Bulletin, an independent UK publication that critically appraises medicines. Reviewed published clinical evidence for Sativex in MS spasticity.
Why This Research Matters
Independent drug evaluation bulletins help clinicians make prescribing decisions. This assessment from a source without industry ties provided a balanced perspective on where Sativex fits in the treatment pathway.
The Bigger Picture
The licensing restriction to patients who failed other treatments and who demonstrated initial response reflected a pragmatic approach to a drug with modest average effect sizes but meaningful benefits for the subset who respond.
What This Study Doesn't Tell Us
Brief review format. Limited critical detail on the magnitude of treatment effects. The publication predated longer-term efficacy and safety data.
Questions This Raises
- ?Is the initial trial period approach the most efficient way to identify responders?
- ?How does Sativex cost-effectiveness compare to other spasticity treatments?
- ?Should the licensing criteria be broader or narrower?
Trust & Context
- Key Stat:
- First cannabinoid preparation licensed for medical use in the UK
- Evidence Grade:
- Independent drug evaluation review. Provides an unbiased assessment but is brief and does not add new data.
- Study Age:
- Published in 2012. Sativex prescribing in the UK has continued, though access varies by region.
- Original Title:
- What place for ▾ cannabis extract in MS?
- Published In:
- Drug and therapeutics bulletin, 50(12), 141-4 (2012)
- Authors:
- Database ID:
- RTHC-00536
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
Who can get Sativex in the UK?
Sativex was licensed for adults with moderate to severe MS spasticity who had not responded adequately to other anti-spasticity medications. Patients must show clinically significant improvement during an initial trial period to continue treatment.
Is Sativex the first choice for MS spasticity?
No. Sativex is positioned as add-on therapy after other treatments have been tried. It is reserved for patients whose spasticity is not adequately controlled by conventional medications.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-00536APA
. (2012). What place for ▾ cannabis extract in MS?. Drug and therapeutics bulletin, 50(12), 141-4. https://doi.org/10.1136/dtb.2012.11.0150
MLA
. "What place for ▾ cannabis extract in MS?." Drug and therapeutics bulletin, 2012. https://doi.org/10.1136/dtb.2012.11.0150
RethinkTHC
RethinkTHC Research Database. "What place for ▾ cannabis extract in MS?" RTHC-00536. Retrieved from https://rethinkthc.com/research/unknown-2012-what-place-for-cannabis
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.